No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients

Kidney International

Volumn 86, Issue 3, 2014, Pages 625-637

  Peters, Christian D ^a,b   Kjaergaard, Krista D ^a,b   Jensen, Jens D ^a,b   Christensen, Kent L ^a   Strandhave, Charlotte ^c   Tietze, Ida N ^d   Novosel, Marija K ^e   Bibby, Bo M ^b   Jensen, Lars T ^f   Sloth, Erik ^a   Jespersen, Bente ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d VIBORG HOSPITAL   (Denmark)

^e Fredericia Sygehus   (Denmark)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

blood pressure; hemodialysis; left ventricular hypertrophy; pulse wave velocity; randomized controlled trials; renin angiotensin system

Indexed keywords

ACETYLSALICYLIC ACID; ALFACALCIDOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ACETATE; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; ERYTHROPOIETIN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LANTHANUM; NORADRENALIN; PLACEBO; PREDNISOLONE; SEVELAMER; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TETRAZOLE DERIVATIVE;

ADULT; AGED; AORTA PRESSURE; ARTERIAL STIFFNESS; CARDIOVASCULAR EFFECT; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART RATE VARIABILITY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORADRENALIN BLOOD LEVEL; NOTE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; URINE VOLUME; VERY ELDERLY; ARTERIAL PRESSURE; BLOOD; DRUG EFFECTS; HEART RATE; HEART VENTRICLE; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; RENAL REPLACEMENT THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARTERIAL PRESSURE; BIPHENYL COMPOUNDS; CATECHOLAMINES; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HEART VENTRICLES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; ORGAN SIZE; PEPTIDE FRAGMENTS; PULSE WAVE ANALYSIS; RENAL DIALYSIS; TETRAZOLES; VASCULAR STIFFNESS;

EID: 84907598714     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.69     Document Type: Article

References (68)

1. de Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 1782-1789.
2. Heerspink HJ, Ninomiya T, Zoungas S et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015.
3. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
4. Asmar R, London G, O'Rourke M et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38: 922-926.
5. Boutouyrie P, Achouba A, Trunet P et al. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 2010; 55: 1314-1322.
6. Safar ME, Blacher J, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 735-738.
7. Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99 : 2434-2439.
8. Verbeke F, Van Biesen W, Honkanen E et al. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the Calcification Outcome in Renal Disease (CORD) Study. Clin J Am Soc Nephrol 2011; 6: 153-159.
9. Laurent S, Cockcroft J, Van BL et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605.
10. Ichihara A, Hayashi M, Kaneshiro Y et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis 2005; 45 : 866-874.
11. Paniagua R, Ventura MD, Avila-Díaz M et al. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant 2010; 25: 551-557.
12. Madsen LH, Ladefoged S, Corell P et al. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007; 71: 548-554.
13. Sommerer C, Beimler J, Schwenger V et al. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 2007; 37 : 350-356.
14. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
15. Silberberg JS, Barre PE, Prichard SS et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-290.
16. Tai D, Lim T, James M et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol 2010; 5: 623-630.
17. Yang LY, Ge X, Wang YL et al. Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis. Am J Med Sci 2013; 345: 1-9.
18. Converse RL, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918.
19. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359.
20. Rubinger D, Backenroth R, Sapoznikov D. Sympathetic nervous system function and dysfunction in chronic hemodialysis patients. Semin Dial 2013; 26: 333-343.
21. Klein IH, Ligtenberg G, Oey PL et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14: 425-430.
22. Takahashi A, Takase H, Toriyama T et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant 2006; 21: 2507-2512.
23. Suzuki H, Kanno Y, Sugahara S et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52: 501-506.
24. Cice G, Di Benedetto A, D'Isa S et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010; 56: 1701-1708.
25. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324.
26. Iseki K, Arima H, Kohagura K et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant 2013; 28: 1579-1589.
27. Yu WC, Lin YP, Lin IF et al. Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis 2006; 47: 478-484.
28. Chang TI, Friedman GD, Cheung AK et al. Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study. J Hum Hypertens 2011; 25: 98-105.
29. Mazzuchi N, Carbonell E, Fernández-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58: 2147-2154.
30. Peters CD, Kjærgaard KD, Jespersen B et al. Renal and cardiovascular effects of irbesartan in dialysis patients - a randomized controlled trial protocol (SAFIR study). Dan Med J 2013; 60: A4602.
31. KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. http://www.kidney.org/professionals/KDOQI/guidelines-commentaries. cfm.
32. London GM, Pannier B, Guerin AP et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90: 2786-2796.
33. London GM, Pannier B, Vicaut E et al. Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition. J Hypertens 1996; 14: 1139-1146.
34. Suzuki H, Nakamoto H, Okada H et al. A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv Perit Dial 2003; 19: 59-66.
35. Tycho Vuurmans JL, Boer WH, Bos WJ et al. Contribution of volume overload and angiotensin II to the increased pulse wave velocity of hemodialysis patients. J Am Soc Nephrol 2002; 13: 177-183.
36. London GM, Blacher J, Pannier B et al. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38: 434-438.
37. Covic A, Mardare N, Gusbeth-Tatomir P et al. Arterial wave reflections and mortality in haemodialysis patients-only relevant in elderly, cardiovascularly compromised? Nephrol Dial Transplant 2006; 21: 2859-2866.
38. London GM, Marchais SJ, Guerin AP et al. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int Suppl 2003; 84: S88-S93.
39. Guerin AP, Blacher J, Pannier B et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103: 987-992.
40. Shigenaga A, Tamura K, Dejima T et al. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin Pract 2009; 112: c31-c40.
41. Mitsuhashi H, Tamura K, Yamauchi J et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009; 207 : 186-190.
42. Jacobs LH, van de Kerkhof JJ, Mingels AM et al. Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. Nephrol Dial Transplant 2010; 25: 243-248.
43. Onofriescu M, Mardare NG, Segall L et al. Randomized trial of bioelectrical impedance analysis vs. clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness. Int Urol Nephrol 2012; 44: 583-591.
44. Khalifeh N, Haider D, Hörl WH. Natriuretic peptides in chronic kidney disease and during renal replacement therapy: an update. J Investig Med 2009; 57: 33-39.
45. Rosner MH. Measuring risk in end-stage renal disease: is N-terminal pro brain natriuretic peptide a useful marker? Kidney Int 2007; 71: 481-483.
46. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340 : 1321-1328.
47. Ondocin PT, Narsipur SS. Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis. Nephrology (Carlton) 2006; 11: 497-501.
48. Weinbergova O, Metelka R, Vymetal J et al. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004; 148: 69-73.
49. Neumann J, Ligtenberg G, Klein II et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-1576.
50. Nunan D, Sandercock GR, Brodie DA. A quantitative systematic review of normal values for short-term heart rate variability in healthy adults. Pacing Clin Electrophysiol 2010; 33: 1407-1417.
51. Eisenhofer G, Huysmans F, Pacak K et al. Plasma metanephrines in renal failure. Kidney Int 2005; 67: 668-677.
52. Agarwal R, Sinha AD, Light RP. Toward a definition of masked hypertension and white-coat hypertension among hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 2003-2008.
53. Hur E, Usta M, Toz H et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis 2013; 61: 957-965.
54. Daugirdas JT. Bioimpedance technology and optimal fluid management. Am J Kidney Dis 2013; 61: 861-864.
55. Sica DA, Marino MR, Hammett JL et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997; 62: 610-618.
56. Marino MR, Langenbacher K, Ford NF et al. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998; 38: 246-255.
57. Frimodt-Moller M, Nielsen AH, Kamper AL et al. Reproducibility of pulse-wave analysis and pulse-wave velocity determination in chronic kidney disease. Nephrol Dial Transplant 2008; 23 : 594-600.
58. Atcor Medical Technical Note No: 14 Assuring Quality of Pulse Wave Analysis Measurements. http://atcormedical.com/technical-notes.html.
59. Papaioannou TG, Protogerou AD, Nasothimiou EG et al. Assessment of differences between repeated pulse wave velocity measurements in terms of 'bias' in the extrapolated cardiovascular risk and the classification of aortic stiffness: is a single PWV measurement enough? J Hum Hypertens 2011; 26 : 594-602.
60. Van Bortel LM, Laurent S, Boutouyrie P et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotidfemoral pulse wave velocity. J Hypertens 2012; 30: 445-448.
61. Vermeersch SJ, Rietzschel ER, De Buyzere ML et al. Distance measurements for the assessment of carotid to femoral pulse wave velocity. J Hypertens 2009; 27: 2377-2385.
62. Mattace-Raso FUS, Hofman A, Verwoert GC et al. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010; 31: 2338-2350.
63. Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
64. Malik M, Bigger JT, Camm AJ et al. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996; 17: 354-381.
65. Risk M, Bril V, Broadbridge C et al. Heart rate variability measurement in diabetic neuropathy: review of methods. Diabetes Technol Ther 2001; 3: 63-76.
66. Roche Diagnostics N-terminal pro B-type natriuretic peptide product sheet (version 7).
67. Karl J, Borgya A, Gallusser A et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999; 230: 177-181.
68. Radioimmunoassay (RIA) for the high-sensitive quantitative determination of Adrenaline (Epinephrine) and Noradrenaline (Norepinephrine) in plasma. http://www.ldn.de/sites/default/files/downloads/MSDS%20BA%20R-4500%202- CAT%20Plasma%20RIA%20%20High%20Sensitive%20en.pdf.